Ocugen OCGN
NASDAQ OCGN
$0.79 -0.03 (-3.08%)
At close: Oct 22, 2026 · 4:00 PM EDT

Ocugen (OCGN) Current Deferred Revenue (2018)

Updated

Ocugen's Current Deferred Revenue came in at $5 million for Q3 2018, down 33.3% from the prior quarter.

Analysis

Ocugen (OCGN) Current Deferred Revenue (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Ocugen 268.71 Mn 85.22 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 5.00 Mn
Jun 30, 2018 7.50 Mn
Mar 31, 2018 5.00 Mn
API Access

Ocugen Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=OCGN&period=max&api_key=YOUR_API_KEY